The Handelsblatt reports that DiGA manufacturers are complaining about cases in which some health insurance companies are trying to divert patients from a medically prescribed DiGA to another, cheaper DiGA in the same indication area and thus interfere with the doctor’s medical decision. A DiGA start-up has now filed a lawsuit against a guild fund because of this practice.
Between mid-2021 and mid-2022, the share of annual costs for DiGAs for statutory health insurance companies was a modest 0.01 percent.